CN103193795B - Pharmaceutical composition of amoxicillin sodium and sulbactam sodium - Google Patents
Pharmaceutical composition of amoxicillin sodium and sulbactam sodium Download PDFInfo
- Publication number
- CN103193795B CN103193795B CN201310114434XA CN201310114434A CN103193795B CN 103193795 B CN103193795 B CN 103193795B CN 201310114434X A CN201310114434X A CN 201310114434XA CN 201310114434 A CN201310114434 A CN 201310114434A CN 103193795 B CN103193795 B CN 103193795B
- Authority
- CN
- China
- Prior art keywords
- sulbactam
- pharmaceutical composition
- sodium
- solution
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)([C@](C(*)=O)N([C@]1C2)C2=O)S1(=O)=O Chemical compound CC(C)([C@](C(*)=O)N([C@]1C2)C2=O)S1(=O)=O 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine, and particularly relates to a pharmaceutical composition of amoxicillin sodium and sulbactam sodium. The pharmaceutical composition is an injection; the sulbactam sodium compound in the pharmaceutical composition utilizes an X-ray powder diffraction spectrum which is measured by a Cu-Kalpha ray and shown in the figure 1. The sulbactam sodium provided by the invention has good storage stability; and the pharmaceutical composition of amoxicillin sodium and sulbactam sodium has better storage stability, and higher use security. In addition, the pharmaceutical composition of the amoxicillin sodium and the sulbactam sodium has better accumulation, synergism and supplementary effects, and better bioavailability.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of sulbactam sodium compound and with the pharmaceutical composition of Amoxicillin Sodium.
Background technology
Sulbactam Chinese another name: (2S, 5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid sodium-4,4-dioxide; (2S-CIS)-3,3-dimethyl-7-oxo-4-sulfo--1-azabicyclo [3,2,0] heptane-2-carboxylic acid 4,4-dioxide sodium salt; English name Sulbactam Sodium; Molecular formula: C
8h
10nNaO
5s; Molecular weight: 255.22; Molecular structural formula is as follows:
Sulbactam is irreversible competitive beta-lactamase inhibitor, the β-lactamase that gram-positive and negative bacterium (except Pseudomonas aeruginosa) are produced all has restraining effect, with make enzyme deactivation after irreversible the reaction occurs enzyme, inhibitor can not make the activity of enzyme be restored after removing.In such cases, enzyme inhibition itself is inevitably destroyed in the process of enzyme, therefore claim suicide inhibitor; Because the prolongation of inhibitory enzyme effect along with the time strengthens, so also claim carrying out property inhibitor, sulbactam and clavulanic acid all belong to this type of.Sulbactam only has stronger anti-microbial activity to gonococcus and meningococcus, and its MIC is respectively 0.1～3.2 μ g/ml and 0.1～0.2 μ g/ml.Effect to other bacteriums is very poor, to the MIC of golden Portugal bacterium, staphylococcus epidermidis, hemophilus influenza, Shigella, Corynebacterium diphtheriae etc., is 25～400 μ g/ml, and the MIC of other enterobacteriaceae lactobacteriaceaes is surpassed to 50 μ g/ml more.Enterococcus spp and Pseudomonas aeruginosa are to this product resistance.Sulbactam has very strong and irreversible restraining effect to the β-lactamase of golden Portugal bacterium and the generation of most gram negative bacilli.2 μ g/ml concentration are very strong to the restraining effect of Richmond-Syks II, III, IV and V type β-lactamase, but to I type β-lactamase without effect.Cooperative phenomenon can occur when penicillins and cephalosporins and sulbactam share, make within the MIC of golden Portugal bacterium to front two class antibiotics resistances, hemophilus influenza, intestinal bacteria, bacteroides fragilis etc. drops to sensitive range.
Amoxicillin Sodium chemical name (2S, 5R, 6R)-3,3-dimethyl-6-[(R)-(-)-2-amino-2-(4-hydroxy phenyl) kharophen]-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-formic acid trihydrate.English name Amoxicillin; Molecular formula C
16h
19n
3o
5s3H
2o; Molecular weight 419.46; Structural formula is as follows:
Amoxycilline Trihydrate bp, have another name called amoxicillin or Amoxicillin, is a kind of the most frequently used penicillins wide spectrum β-lactam antibitics, is a kind of white powder, and the transformation period is about 61.3 minutes.Stable under acidic conditions, the gastrointestinal absorption rate reaches 90.The Amoxicillin Sodium germicidal action is strong, and the ability of permeates cell membranes is also strong.It is one of current widely used oral penicillin.
CN200910169645.7 discloses a kind of process for purification of sulbactam sodium compound, and the method comprises the following steps: a. is at first water-soluble by the sulbactam crude product, and the pH value of its aqueous solution is adjusted to acidity, collects the solid of separating out in solution; B., after solid step a obtained is used the organic solvent dissolution mixed with it, make and treat refining solution; C. will treat that refining solution is placed in macroporous adsorbent resin, eluent wash-out purifying, collect elutriant; D. the elutriant pH value that regulating step c obtains, for neutral, is collected the solid of separating out, and obtains the sulbactam highly finished product.The sulbactam sodium compound highly finished product purity that adopts the method to obtain reaches more than 99.8%.Yield surpasses 90%.
CN200810134827.6 provides the preparation method of a kind of amoxicillin sodium for injection sulbactam and lyophilized injectable powder thereof, and the separation purification method of the Amoxicillin Sodium of injection and sulbactam.This invention adopts high speed adverse current chromatogram, form the solvent system of stationary phase, moving phase with trichloromethane, ethyl acetate, methyl alcohol, water preparation, Amoxicillin Sodium and sulbactam are carried out to separation and purification, obtain Amoxicillin Sodium and the sulbactam of injection, the products obtained therefrom purity is more than 98%.
The stability in storage of sulbactam of the prior art is poor, in illumination and moist environment, its related substance can significantly increase, the pharmaceutical composition of itself and Amoxicillin Sodium stores for a long time, foreign matter content is higher, safety in utilization is poor, for the Amoxicillin Sodium that obtains a kind of more excellent performance and the pharmaceutical composition of sulbactam, special the present invention proposed.
Summary of the invention
The object of the present invention is to provide the pharmaceutical composition of a kind of Amoxicillin Sodium and sulbactam, the pharmaceutical composition provided has better stability in storage, safe to use.
In order to realize the foregoing invention purpose, the present invention takes following technical scheme:
The pharmaceutical composition of a kind of Amoxicillin Sodium and sulbactam, the structural formula of the sulbactam sodium compound in described pharmaceutical composition is:
The X-ray powder diffraction spectrogram that described sulbactam sodium compound is used the Cu-K alpha-ray to measure as shown in Figure 1.
Sulbactam sodium compound provided by the invention is crystal, the change of its internal crystal structure has caused its physicals that variation has also correspondingly occurred, the contriver finds that by stability experiment the special crystallized form of sulbactam sodium compound provided by the present invention compares with the solid form of the sulbactam of prior art, there is stronger stability in storage, and then improved the stability in storage of the pharmaceutical composition of sulbactam sodium compound crystal and Amoxicillin Sodium, with the Amoxicillin Sodium of prior art, with the pharmaceutical composition of sulbactam, compare, the pharmaceutical composition of Amoxicillin Sodium provided by the invention and sulbactam has better stability in storage, greatly improved patient's drug safety.
The preparation method of described sulbactam sodium compound comprises: by N, dinethylformamide and water are mixed with mixed solvent with the volume ratio of 1～3:1, get the sulbactam bulk drug, add N, the mixed solvent of dinethylformamide and water, the volume of described mixed solvent is 3～5ml:1g with the ratio of the quality of sulbactam, be warming up to 60～70 ℃, be stirred to whole dissolvings, insulation, the pH of solution is adjusted to 5.0～5.5, solution is carried out to magnetic treatment, add decolorizing with activated carbon in the solution of handling, filter, obtain settled solution, add ethanol in settled solution, filter, obtain filter cake, washing leaching cake, drying under reduced pressure 2～4h again, obtain the white micro-crystals powder.
In the present invention, the contriver is by experiment repeatedly, constantly change crystallization method and crystallization condition, finally prepare a kind of sulbactam sodium compound crystal with brand-new crystal formation, this sulbactam sodium compound crystal has very high lattice energy, the sulbactam molecule is subject to the lattice constraint larger, has good preservation stability.
The volume of described ethanol and the volume ratio of mixed solvent are 5-10:1.
Described magnetic treatment is: solution is flowed through to the direct magnetic field of 0.5T with the speed of 5～10m/s, field direction is vertical with the flow of solution direction.
It is described that to add the activated carbon degerming be this area common technology means, can process referring to any decolouring, those skilled in the art are without paying any creative work, and the prior art that can grasp according to himself is carried out appropriate selection, and realizes the object of the invention.
In order further to improve the formulation products quality, the present invention also can be preferably be filtered into the use ultrafiltration membrance filter after decolouring.
Preferably, described pharmaceutical composition is injection.
Preferred, described injection is sterile powder injection.
In described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 1:0.25～1.5.
Preferably, in described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 1:0.25～1.
Preferred, in described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 1:0.25～0.5.
The preparation method of described sterile powder injection is: take Amoxicillin Sodium and the described sulbactam of recipe quantity under aseptic condition, be placed in solid powder mixer and evenly mix, the gained raw material proceeds to the sterile preparation workshop, the delicate metering packing, and gland, obtain.
Compared with prior art, Amoxicillin Sodium provided by the invention and tazobactam sodium drug composition have following advantage:
(1) the pharmaceutical composition stability in storage of Amoxicillin Sodium of the present invention and sulbactam is good, and safety performance is higher.
(2) pharmaceutical composition of Amoxicillin Sodium of the present invention and sulbactam has better cumulative, collaborative, complementary action, and its bioavailability is better.
The accompanying drawing explanation
The X-powder diagram of the sulbactam that Fig. 1 provides for the embodiment of the present invention 1.
Embodiment
Below by specific embodiment, summary of the invention of the present invention is described further, but does not therefore limit content of the present invention.
Embodiment 1
The preparation of sulbactam sodium compound
By N, dinethylformamide and water are mixed with mixed solvent with the volume ratio of 3:1, get the sulbactam bulk drug, add N, the mixed solvent of dinethylformamide and water, the volume of described mixed solvent is 5ml:1g with the ratio of the quality of sulbactam, be warming up to 70 ℃, be stirred to whole dissolvings, insulation, the pH of solution is adjusted to 5.5, solution is flowed through to the direct magnetic field of 0.5T with the speed of 5m/s, field direction is vertical with the flow of solution direction, add decolorizing with activated carbon in the complete solution of magnetic treatment, the 0.3%(g/ml that the consumption of gac is the solvent mixture volume), stir 30min, filter, obtain settled solution, add ethanol in settled solution, the volume of described ethanol and the volume ratio of mixed solvent are 5:1, filter, obtain filter cake, with distilled water wash filter cake 3 times, drying under reduced pressure 2～4h again, obtain the white micro-crystals powder.Yield 72.4%, HPLC content 99.78%.
The X-ray powder diffraction spectrogram that uses the Cu-K alpha-ray to measure is shown for Fig. 1.
Embodiment 2
The preparation of sulbactam sodium compound
By N, dinethylformamide and water are mixed with mixed solvent with the volume ratio of 1:1, get the sulbactam bulk drug, add N, the mixed solvent of dinethylformamide and water, the volume of described mixed solvent is 3ml:1g with the ratio of the quality of sulbactam, be warming up to 60 ℃, be stirred to whole dissolvings, insulation, the pH of solution is adjusted to 5.0, solution is flowed through to the direct magnetic field of 0.5T with the speed of 10m/s, field direction is vertical with the flow of solution direction, add decolorizing with activated carbon in the complete solution of magnetic treatment, the 0.3%(g/ml that the consumption of gac is the solvent mixture volume), stir 30min, filter, obtain settled solution, add ethanol in settled solution, the volume of described ethanol and the volume ratio of mixed solvent are 10:1, filter, obtain filter cake, with distilled water wash filter cake 3 times, drying under reduced pressure 2h again, obtain the white micro-crystals powder.Yield 72.4%, HPLC content 99.78%.
The X-ray powder diffraction figure that uses the Cu-K alpha-ray to measure is consistent with the result of embodiment 1.
Embodiment 3
The preparation of Amoxicillin Sodium and sulbactam powder pin
Take the sulbactam of Amoxicillin Sodium and embodiment 1 preparation under aseptic condition, wherein the mass ratio of Amoxicillin Sodium and sulbactam is 4:1, being placed in solid powder mixer evenly mixes, the gained raw material proceeds to the sterile preparation workshop, the delicate metering packing, every bottle contains sulbactam 0.5g, jumps a queue, rolls lid, finished product packing warehouse-in censorship.
Embodiment 4
The preparation of Amoxicillin Sodium and sulbactam powder pin
Take the sulbactam of Amoxicillin Sodium and embodiment 1 preparation under aseptic condition, wherein the mass ratio of Amoxicillin Sodium and sulbactam is 1:1, being placed in solid powder mixer evenly mixes, the gained raw material proceeds to the sterile preparation workshop, the delicate metering packing, every bottle contains sulbactam 3.0g, jumps a queue, rolls lid, finished product packing warehouse-in censorship.
Embodiment 5
The preparation of Amoxicillin Sodium and sulbactam powder pin
Take the sulbactam of Amoxicillin Sodium and embodiment 1 preparation under aseptic condition, wherein the mass ratio of Amoxicillin Sodium and sulbactam is 2:1, being placed in solid powder mixer evenly mixes, the gained raw material proceeds to the sterile preparation workshop, the delicate metering packing, every bottle contains sulbactam 1.5g, jumps a queue, rolls lid, finished product packing warehouse-in censorship.
Embodiment 6
The preparation of Amoxicillin Sodium and sulbactam powder pin
Take the sulbactam of Amoxicillin Sodium and embodiment 1 preparation under aseptic condition, wherein the mass ratio of Amoxicillin Sodium and sulbactam is 4:1, being placed in solid powder mixer evenly mixes, the gained raw material proceeds to the sterile preparation workshop, the delicate metering packing, every bottle contains sulbactam 2.0g, jumps a queue, rolls lid, finished product packing warehouse-in censorship.
Experimental example 1
In this test example sulbactam prepared to embodiment 1～2, related substance detects, and this test is carried out according to 2010 editions second appendix VIII P residual solvent assay method of Chinese Pharmacopoeia, appendix XIX F medicine impurity analysis governing principle, and it the results are shown in Table 1:
The assay of table 1 related substance
| Preparation | DMF | Ethanol | Other related substance |
| Embodiment 1 product | Up to specification | Up to specification | Up to specification |
| Embodiment 2 products | Up to specification | Up to specification | Up to specification |
Experimental example 2
This experimental example has been investigated the stability of sulbactam provided by the invention
This test is carried out according to 2005 editions second appendix XIX C medicine stability test governing principle of Chinese Pharmacopoeia, and result is as follows:
Table 2, accelerated test assay result
| ? | 0 month | 1 month | 3 months | 6 months | 9 months |
| 1 | 99.95% | 99.94% | 99.93% | 99.91% | 99.73% |
| 2 | 99.71% | 99.70% | 99.68% | 99.65% | 99.45% |
| 3 | 99.74% | 99.72% | 99.61% | 99.05% | 98.35% |
| 4 | 99.85% | 99.78% | 99.45% | 99.15% | 98.52% |
Table 3, test of long duration assay result
| ? | 0 month | 3 months | 6 months | 9 months | 15 months | 24 months |
| 1 | 99.95% | 99.93% | 99.90% | 99.85% | 99.70% | 99.58% |
| 2 | 99.71% | 99.69% | 99.65% | 99.60% | 99.41% | 99.21% |
| 3 | 99.74% | 99.70% | 99.65% | 99.30% | 98.64% | 97.80% |
| 4 | 99.85% | 99.75% | 99.40% | 99.11% | 98.50% | 97.74% |
The product that sample 1 is the embodiment of the present invention 1;
The product that sample 2 is the embodiment of the present invention 2;
Sample 3 is that HPLC is 99.74% with reference to the sulbactam of CN200910169645.7 embodiment 1 preparation;
Sample 4 is commercially available sulbactam bulk drug, uses the ethanol/water recrystallization, and HPLC is 99.85%;
Accelerated test and test of long duration by this experimental example are known, and compared with prior art, the stability of sulbactam provided by the invention is better.
Claims (9)
1. the pharmaceutical composition of an Amoxicillin Sodium and sulbactam, is characterized in that, the structural formula of described sulbactam sodium compound is:
The X-ray powder diffraction spectrogram that described sulbactam sodium compound is used the Cu-K alpha-ray to measure as shown in Figure 1.
2. pharmaceutical composition according to claim 1, it is characterized in that, the preparation method of described sulbactam sodium compound comprises: by N, dinethylformamide and water are mixed with mixed solvent with the volume ratio of 1～3:1, get the sulbactam bulk drug, add N, the mixed solvent of dinethylformamide and water, the volume of described mixed solvent is 3～5ml:1g with the ratio of the quality of sulbactam, be warming up to 60～70 ℃, be stirred to whole dissolvings, insulation, the pH of solution is adjusted to 5.0～5.5, solution is carried out to magnetic treatment, add decolorizing with activated carbon in the solution of handling, filter, obtain settled solution, add ethanol in settled solution, filter, obtain filter cake, washing, drying under reduced pressure 2～4h again, obtain the white micro-crystals powder.
3. pharmaceutical composition according to claim 2, is characterized in that, the volume of described ethanol and the volume ratio of mixed solvent are 5-10:1.
4. pharmaceutical composition according to claim 3, is characterized in that, described magnetic treatment is: solution is flowed through to the direct magnetic field of 0.5T with the speed of 5～10m/s, field direction is vertical with the flow of solution direction.
5. pharmaceutical composition according to claim 1, is characterized in that, described described pharmaceutical composition is injection.
6. pharmaceutical composition according to claim 5, is characterized in that, described injection is sterile powder injection.
7. pharmaceutical composition according to claim 6, is characterized in that, in described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 1-4:1.
8. pharmaceutical composition according to claim 7, is characterized in that, in described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 2-4:1.
9. pharmaceutical composition according to claim 8, is characterized in that, in described sterile powder injection, the mass ratio of Amoxicillin Sodium and sulbactam is 2:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310114434XA CN103193795B (en) | 2013-04-03 | 2013-04-03 | Pharmaceutical composition of amoxicillin sodium and sulbactam sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310114434XA CN103193795B (en) | 2013-04-03 | 2013-04-03 | Pharmaceutical composition of amoxicillin sodium and sulbactam sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103193795A CN103193795A (en) | 2013-07-10 |
| CN103193795B true CN103193795B (en) | 2013-12-11 |
Family
ID=48716630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310114434XA Expired - Fee Related CN103193795B (en) | 2013-04-03 | 2013-04-03 | Pharmaceutical composition of amoxicillin sodium and sulbactam sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103193795B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107474130A (en) * | 2017-08-11 | 2017-12-15 | 樊之雄 | A kind of synthetic method of Amoxicillin artificial antigen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720914A (en) * | 2005-07-20 | 2006-01-18 | 夏中宁 | Anti-beta-lactamase antibiotic composite preparation |
| CN101300701A (en) * | 2005-10-29 | 2008-11-05 | 巴斯夫燃料电池有限责任公司 | Membrane for fuel cells, containing polymers comprising phosphonic acid groups and/or sulfonic acid groups, membrane electrode units and the use thereof in fuel cells |
| CN101696211A (en) * | 2009-08-28 | 2010-04-21 | 海南美大制药有限公司 | High-purity sulbactam sodium compound |
-
2013
- 2013-04-03 CN CN201310114434XA patent/CN103193795B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720914A (en) * | 2005-07-20 | 2006-01-18 | 夏中宁 | Anti-beta-lactamase antibiotic composite preparation |
| CN101300701A (en) * | 2005-10-29 | 2008-11-05 | 巴斯夫燃料电池有限责任公司 | Membrane for fuel cells, containing polymers comprising phosphonic acid groups and/or sulfonic acid groups, membrane electrode units and the use thereof in fuel cells |
| CN101696211A (en) * | 2009-08-28 | 2010-04-21 | 海南美大制药有限公司 | High-purity sulbactam sodium compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103193795A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104644640B (en) | A kind of preparation method of cefoperazone sodium and sulbactam sodium for injection powder pin | |
| CN101322702B (en) | Piperacillin sodium and sulbactam sodium for injection and preparation of freeze-dried injection thereof | |
| CN102659818B (en) | Hydrochloric acid cefotiam crystalline compound, preparation method thereof and medicine combination containing compound | |
| CN102268019B (en) | Cefadroxil compound and preparation method thereof | |
| CN105560194B (en) | Cefotaxime powder-injection of high-purity and preparation method thereof | |
| CN104876946A (en) | Sulbactam compound for treating infectious diseases, and preparation method therefor | |
| CN103113390B (en) | Sulbactam sodium compound and medical composition of sulbactam sodium compound and mezlocillin sodium | |
| CN110354113B (en) | Borneol derivative antibacterial agent and preparation method and application thereof | |
| CN101967156A (en) | Method for recrystallizing cefuroxime sodium | |
| CN104873501A (en) | Sulbactam sodium composition for treating infectious diseases | |
| CN104910186A (en) | Cefathiamidine compound | |
| CN104958318A (en) | Medicinal sulbactam sodium composition for treating infectious diseases | |
| CN103193795B (en) | Pharmaceutical composition of amoxicillin sodium and sulbactam sodium | |
| CN104997773A (en) | Anti-infective drug sulbactam sodium composite | |
| CN103127114B (en) | Medicinal composition including piperacillin sodium and sulbactam sodium | |
| CN102627660B (en) | Cefmetazole aseptic powder and its preparation method | |
| CN103232477B (en) | Cefotiam hydrochloride compound, and preparation method and pharmaceutical composition thereof | |
| CN103230400A (en) | Drug composition of cefoperazone sodium and tazobactam sodium and preparation method thereof | |
| CN102274233A (en) | Medicinal composition of cefoperazone sodium and tazobactam sodium | |
| CN103142617B (en) | Cefuroxime lysine medicinal composition | |
| CN104650115A (en) | Cefoperazone sodium, special superfine compound powder preparation thereof and preparation method of special superfine compound powder preparation | |
| CN102824304B (en) | Cefepime hydrochloride composition for injection and its preparation method | |
| CN102329328B (en) | Novel method for purifying ceftizoxime sodium compound | |
| CN104926835A (en) | Cefotiam hydrochloride compound, method for preparing same and pharmaceutical composition with cefotiam hydrochloride compound | |
| CN105622635A (en) | Ceftizoxime sodium novel crystal form capable of reducing anaphylactic reactions and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130710 Assignee: Sichuan Pharmaceutical Inc. Assignor: Sichuan Province Huida Pharmaceutical Co., Ltd. Contract record no.: 2014510000009 Denomination of invention: Pharmaceutical composition of amoxicillin sodium and sulbactam sodium Granted publication date: 20131211 License type: Exclusive License Record date: 20140228 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131211 Termination date: 20180403 |